MyHealthTest (MHT), a division of ITL Health Group (ASX:ITD) that creates and markets highly innovative direct to consumer pathology testing for major chronic diseases, is very pleased to announce it has been granted accreditation for its testing laboratory to the ISO15189 and NPAAC (National Pathology Accreditation Advisory Council) standards by the National Association of Testing Authorities (NATA) and the Royal College of Pathologists of Australasia (RCPA).
|16th May 2017||Completion of Development of Glasses-Free 3D Chip||Download|
|15th May 2017||ITL Investor Update||Download|
|12th May 2017||Share Consolidation Completion||Download|
|10th May 2017||Change in Director Interest Notice||Download|
|9th May 2017||Results of Meeting||Download|
|2nd May 2017||Share Consolidation Commencement||Download|
|2nd May 2017||MyHealthTest Achieves Laboratory Accreditation||Download|
|28th Apr 2017||Appendix 4C - quarterly||Download|
|19th Apr 2017||ITL awarded Supply Agreement with NZ Blood Service||Download|
|18th Apr 2017||Update on Share Consolidation||Download|
|7th Apr 2017||Notice of Annual General Meeting/Proxy Form||Download|
|6th Apr 2017||Update on Form 20-F for Proposed NASDAQ Dual Listing||Download|
|3rd Apr 2017||Release of 2016 Audited Financial Results||Download|
|3rd Apr 2017||Annual Report to shareholders||Download|
|3rd Apr 2017||Appendix 4G||Download|
|28th Mar 2017||ITL Achieves Record Month||Download|
|3rd Mar 2017||Results of Meeting||Download|
|1st Mar 2017||Preliminary Final Report||Download|
|27th Feb 2017||Update on Form 20-F for Proposed Nasdaq Dual Listing||Download|
|27th Feb 2017||ITL Global rebrand to ITL Health Group||Download|
|20th Feb 2017||ITL Corporate & BioMedical Growth Update||Download|
|20th Feb 2017||Boardroom Radio Interview Mr Bill Mobbs CEO ITL||Download|
|20th Feb 2017||Substantial Holding in ITL Notice - TBF||Download|
|17th Feb 2017||ITL Appendix 4D & Financial Statements Dec 2016||Download|
|17th Feb 2017||ITL Profit Doubles in Half Year 2016-17 Results||Download|
|2nd Feb 2017||Submission of Nasdaq Listing Application Form||Download|
|2nd Feb 2017||Notice of Extraordinary General Meeting/Proxy Form||Download|
|31st Jan 2017||Appendix 4C - quarterly||Download|
ITL Health Group (ASX:ITD), an innovative global medical technology company, is pleased to announce that in February the Company recorded its highest monthly revenue and profit in its 23-year history. ITL BioMedical and ITL Healthcare both achieved record months. Read More “ITL Achieves Record Month”
ITL Limited (ASX:ITD), an innovative global medical technology company, supplier and strategic partner that provides innovative products and solutions to healthcare markets and empowers individual health management, formally announces its rebrand to ITL Health Group (ITL).
Following the strong first half results announced on Friday 17th February the company is issuing the following presentation – “Half year results 2016/17 and ITL BioMedical Growth Update” – in order to provide greater insight into ITL’s innovative products range and the exciting growth opportunities in the BioMedical division.
ITL Limited is pleased to provide the opportunity to listen to an audio interview with Mr Bill Mobbs, Executive Chairman.
Mr Mobbs talks about the Company’s strong first half results that saw revenue rise 11%, EBITDA up 69% and profit before tax grow 110% versus the previous comparative period, and provides an insight into ITL’s innovative products range and the exciting growth opportunities in the BioMedical division.
ITL Limited (“ITL”), an innovative diversified healthcare company, is pleased to announce excellent results for the half year ended 31 December 2016 compared with the previous corresponding period.
Founder and Executive Chairman Mr. Bill Mobbs has released a parcel of his 42% of ITL (4.6m shares) to a Specialist Small Cap Fund Manager and to fellow ITL non-executive Director Mr. Mark Peatey. Mr. Mobbs retains 36% of ITL.
ITL BioMedical, a division of ITL that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce the global launch of its highly innovative patented DonorCare® Needle Guard 2 will take place at the AABB Annual Meeting in Orlando, the premiere event for healthcare professionals in transfusion medicine and cellular therapies. Read More “ITL BioMedical Announces Global Launch of DonorCare Needle Guard 2”
ITL BioMedical, a division of ITL (ASX: ITD) that sets industry standards for the innovative design and production of biological sampling systems for human and animal use, is pleased to announce it has signed a global, multi-year distribution agreement for its SampLok® Sampling Kit (SSK) with bioMérieux (Euronext: BIM), a multinational biotechnology company and supplier of bacterial screening test systems and ancillaries. Read More “ITL BioMedical Announces Global Distribution Agreement for SSK with bioMérieux”
ITL Limited, a diversified healthcare company and owner of ITL Healthcare which produces quality invasive blood pressure monitoring systems, is pleased to announce a new five year contract with Macquarie University Hospital (MUH), Australia’s first private not-for-profit teaching hospital, located at Macquarie University in Sydney. Read More “5 Year Contract Win with Macquarie University Hospital”